Peripheral blood progenitor cell collection in pediatric patients optimized by high pre-apheresis count of circulating CD34+ cells and high blood flow

Axel Karow, Kurt Leibundgut(Swiss Red Cross), Anna Wilhelm(University of Bern), Thomas Pabst(University Hospital of Bern), Roland A. Ammann(University of Bern), Gabriela M. Baerlocher(Terry Fox Research Institute), Behrouz Mansouri Taleghani(University of Bern), Jochen Roessler(University of Bern)

Bone Marrow Transplantation

October 23, 2018

10.1038/s41409-018-0353-8

Cited by 10

Related Papers

Mutations in <i>TERT,</i> the Gene for Telomerase Reverse Transcriptase, in Aplastic Anemia

|New England Journal of Medicine|2005|717

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

|Leukemia|2012|417

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

|Leukemia|2017|339

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

|Journal of Clinical Oncology|2013|299

Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

|Blood|2011|289